Back to Search Start Over

PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer

Authors :
Paula Ghaneh
Robert Hanson
Andrew Titman
Gill Lancaster
Catrin Plumpton
Huw Lloyd-Williams
Seow Tien Yeo
Rhiannon Tudor Edwards
Colin Johnson
Mohammed Abu Hilal
Antony P Higginson
Tom Armstrong
Andrew Smith
Andrew Scarsbrook
Colin McKay
Ross Carter
Robert P Sutcliffe
Simon Bramhall
Hemant M Kocher
David Cunningham
Stephen P Pereira
Brian Davidson
David Chang
Saboor Khan
Ian Zealley
Debashis Sarker
Bilal Al Sarireh
Richard Charnley
Dileep Lobo
Marianne Nicolson
Christopher Halloran
Michael Raraty
Robert Sutton
Sobhan Vinjamuri
Jonathan Evans
Fiona Campbell
Jon Deeks
Bal Sanghera
Wai-Lup Wong
John P Neoptolemos
Source :
Health Technology Assessment, Vol 22, Iss 7 (2018)
Publication Year :
2018
Publisher :
NIHR Journals Library, 2018.

Abstract

Background: Pancreatic cancer diagnosis and staging can be difficult in 10–20% of patients. Positron emission tomography (PET)/computed tomography (CT) adds precise anatomical localisation to functional data. The use of PET/CT may add further value to the diagnosis and staging of pancreatic cancer. Objective: To determine the incremental diagnostic accuracy and impact of PET/CT in addition to standard diagnostic work-up in patients with suspected pancreatic cancer. Design: A multicentre prospective diagnostic accuracy and clinical value study of PET/CT in suspected pancreatic malignancy. Participants: Patients with suspected pancreatic malignancy. Interventions: All patients to undergo PET/CT following standard diagnostic work-up. Main outcome measures: The primary outcome was the incremental diagnostic value of PET/CT in addition to standard diagnostic work-up with multidetector computed tomography (MDCT). Secondary outcomes were (1) changes in patients’ diagnosis, staging and management as a result of PET/CT; (2) changes in the costs and effectiveness of patient management as a result of PET/CT; (3) the incremental diagnostic value of PET/CT in chronic pancreatitis; (4) the identification of groups of patients who would benefit most from PET/CT; and (5) the incremental diagnostic value of PET/CT in other pancreatic tumours. Results: Between 2011 and 2013, 589 patients with suspected pancreatic cancer underwent MDCT and PET/CT, with 550 patients having complete data and in-range PET/CT. Sensitivity and specificity for the diagnosis of pancreatic cancer were 88.5% and 70.6%, respectively, for MDCT and 92.7% and 75.8%, respectively, for PET/CT. The maximum standardised uptake value (SUVmax.) for a pancreatic cancer diagnosis was 7.5. PET/CT demonstrated a significant improvement in relative sensitivity (p = 0.01) and specificity (p = 0.023) compared with MDCT. Incremental likelihood ratios demonstrated that PET/CT significantly improved diagnostic accuracy in all scenarios (p

Details

Language :
English
ISSN :
13665278 and 20464924
Volume :
22
Issue :
7
Database :
Directory of Open Access Journals
Journal :
Health Technology Assessment
Publication Type :
Academic Journal
Accession number :
edsdoj.f568c5cf6bee4030904cc08b700c1204
Document Type :
article
Full Text :
https://doi.org/10.3310/hta22070